title: Stress ulcer prophylaxis and ventilation pneumonia: prevention by antibacterial cytoprotective agents?
abstract: The gastric and tracheal flora of 142 consecutive patients receiving stress ulcer prophylaxis were investigated, identifying identical isolates by typing. Furthermore, the growth pattern of normal respiratory bacteria and organisms causing ventilation pneumonia at different pH values and the in vitro effect of sucralfate and bismuth subsalicylate on these bacteria in simulated gastric fluid were studied. The results obtained were as follows: (1) with rising gastric pH bacterial counts in gastric aspirates, especially gram-negatives, increased significantly; (2) in 45 (31.7%) of the patients identical organisms were first isolated in gastric samples and one to two days later in tracheal secretions; (3) ventilation pneumonia was significantly more frequent in patients with high gastric pH; (4) pathogens causing ventilation pneumonia grew well in simulated gastric fluid at higher pH values, unlike normal respiratory organisms; and (5) sucralfate and bismuth subsalicylate showed antibacterial activity against frequent causative organisms of ventilation pneumonia.
authors.affiliation: Department of Hospital Epidemiology, University Hospital of Freiburg, Federal Republic of Germany.
authors.forename: F
authors.initials: F
authors.lastname: Daschner
authors.forename: I
authors.initials: I
authors.lastname: Kappstein
authors.forename: I
authors.initials: I
authors.lastname: Engels
authors.forename: K
authors.initials: K
authors.lastname: Reuschenbach
authors.forename: J
authors.initials: J
authors.lastname: Pfisterer
authors.forename: N
authors.initials: N
authors.lastname: Krieg
authors.forename: W
authors.initials: W
authors.lastname: Vogel
mesh_terms: D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D000897:Anti-Ulcer Agents / Q000627:therapeutic use*; D001729:Bismuth; D005750:Gastric Juice / Q000382:microbiology; D006801:Humans; D006863:Hydrogen-Ion Concentration; D009942:Organometallic Compounds / Q000627:therapeutic use; D010437:Peptic Ulcer / Q000517:prevention & control*; D011014:Pneumonia / Q000382:microbiology* / Q000517:prevention & control; D011446:Prospective Studies; D012121:Respiration, Artificial / Q000009:adverse effects*; D012307:Risk Factors; D012459:Salicylates / Q000627:therapeutic use; D013312:Stress, Physiological / Q000150:complications*; D013392:Sucralfate / Q000627:therapeutic use; D014132:Trachea / Q000382:microbiology
chemical_list: D000900:Anti-Bacterial Agents; D000897:Anti-Ulcer Agents; D009942:Organometallic Compounds; D012459:Salicylates; D013392:Sucralfate; C015715:bismuth subsalicylate; D001729:Bismuth